The FGD1 Knockout Raji Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte cell line, with targeted disruption of the FGD1 gene. This loss-of-function model is designed for investigation of FGD1-dependent signaling and cytoskeletal regulation in a B-cell context.
The Raji cell line originates from a Burkitt’s lymphoma patient and is Epstein-Barr virus (EBV)-positive. As B lymphocytes, Raji cells are widely employed in immunology and cancer research due to their capacity for antigen presentation, antibody production, and robust B-cell receptor (BCR) signaling. Their EBV-transformed background provides a relevant model for studying lymphomagenesis and B-cell malignancies.
FGD1 encodes a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPase Cdc42 by promoting its GTP-bound state. Active Cdc42 subsequently stimulates downstream effectors including PAK1, WASP, and the ARP2/3 complex, orchestrating actin cytoskeleton reorganization, filopodia formation, and cell migration. FGD1 activity is regulated by upstream signals from the BCR, CD40 ligand, and integrin-mediated pathways, and may involve interactions with phosphatidylinositol lipids, cortactin, and other actin regulatory proteins. This positions FGD1 at a critical node linking extracellular cues to cytoskeletal dynamics.
In the Raji B lymphocyte model, FGD1 is implicated in BCR-dependent cytoskeletal remodeling, cell polarization, and migration processes essential for immune function. Disruption of FGD1 in these cells allows dissection of its role in B-cell signaling, adhesion, and morphological responses downstream of BCR and CD40 stimulation. Moreover, since FGD1 mutations cause Aarskog-Scott syndrome and faciogenital dysplasia, this polyclonal knockout model offers a platform to explore disease mechanisms associated with Cdc42 dysfunction in an immune cell background.
Researchers can utilize these polyclonal knockout cells to perform detailed studies of B-cell cytoskeletal dynamics, migration/invasion, and BCR signal transduction. Compatible assays include Western blotting, immunofluorescence, flow cytometry, Ca2? flux analysis, RNA-seq, and phospho-signaling interrogation. The polyclonal format ensures a heterogeneous population representative of the knockout effect without clonal biases, suitable for population-level phenotypic screens and drug response profiling. For additional information, please contact Ascent Research.
